STVN
Overvalued by 188.1% based on the discounted cash flow analysis.
Market cap | $5.17 Billion |
---|---|
Enterprise Value | $5.58 Billion |
Dividend Yield | $0.06 (0.305745914602003%) |
Earnings per Share | $0.54 |
Beta | 0.58 |
Outstanding Shares | 272,789,169 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 38.48 |
---|---|
PEG | -185.33 |
Price to Sales | 7.49 |
Price to Book Ratio | 4.5 |
Enterprise Value to Revenue | 5.13 |
Enterprise Value to EBIT | 36.48 |
Enterprise Value to Net Income | 48 |
Total Debt to Enterprise | 0.09 |
Debt to Equity | 0.36 |
No data
No data
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end por...